From: Precision BioLogic Inc.
Date: September 10th, 2025
Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the expanded utility of its CRYOcheck Chromogenic Factor VIII assay in anticipation of emerging hemophilia treatments such as Mim8, a next generation bispecific antibody for the treatment of hemophilia A.
Precision BioLogic originally developed CRYOcheck Chromogenic Factor VIII in response to a growing demand for chromogenic assays1. Launched in 2020, it was the first commercially available, FDA-cleared chromogenic factor VIII (FVIII) assay designed for use on automated instruments and was readily welcomed by clinical labs to help identify FVIII deficiency and aid in the management of hemophilia A. And now Precision BioLogic is again leading the way in bringing novel, cleared solutions to clinical labs conducting hemophilia testing.
“We took a great assay and made it even better,” explains Paul Empey, President & CEO of Precision BioLogic. “We want to ensure labs are ready and able to deliver accurate results when new treatments become available. And we want to make doing that as easy as possible for labs.”